Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07353671
PHASE2/PHASE3

Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

Sponsor: West China Hospital

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.

Official title: A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-03-01

Completion Date

2027-06-30

Last Updated

2026-03-25

Healthy Volunteers

No

Interventions

DRUG

Topical application of Periplaneta americana-derived Meilian Fuxin Solution

A topical formulation derived from Periplaneta americana (Meilian Fuxin Solution).

OTHER

Topical application of placebo

The placebo topical formulation will be composed of inactive ingredients and will be matched in appearance, texture, and administration regimen to the active Periplaneta americana-derived Meilian Fuxin Solution, and participants will also receive standard skin care for radiation dermatitis according to institutional clinical practice guidelines.

RADIATION

Radiotherapy

One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.

Locations (2)

Sichuan University West China Hospital, Chengdu, Sichuan

Chengdu, Sichuan, China

Sichuan University West China Hospital

Chengdu, Sichuan, China